Suprachoroidal Injection of Triamcinolone with 30 Gauge Needle using Novel Suprachoroidal Injection Device: Long term Evaluation

Author: Ajay Aurora (India)

Co-authors: Arjun Aurora, Ritu Aurora

Purpose

Evaluate safety & efficacy of Suprachoroidal Injection of Triamcinolone Acetonide (SCITA) with novel Suprachoroidal Injection Device (SCID) in patients with macular edema due to diverse retinal pathology and in cases of uveitis and to evaluate the long-term efficacy after repeat injections

Setting/Venue

Non-randomised interventional case series in a tertiary care retina practice

Methods

SCITA 0.1ml/4mg was given in 76 eyes of 72 patients with 30G needle using novel SCID . Eight patients had repeat second injection and two had a third repeat injection. The angulation of the base plate to the scleral entry was a critical determinant of correct plane of injection. BCVA, IOP and central subfield thickness (CST/SDOCT) was measured on day (D) 1, 7, 30,60 and 90

Results

SCITA was pain free, well tolerated and no eye developed retinal/choroidal injury. However in 6 eyes the injection became intravitreal four of them requiring antiglaucoma medications Mean baseline CST (486µm) decreased to normal range (246 µm) at D7; was maintained at232µm/ D30 & 309 µm/ D90. Edema resolution occurred in 66% at D30 & 57% eyes remained edema free at D90. BCVA improved 1 line in 59% & 3 lines in 35% at D30. No eye had increased IOP if there was no intravitreal injection of Triamcinolone (TA)

Conlusions

SCITA using the novel SCID is cheap, safe, effective, well tolerated and devoid of adverse ocular event. It does require a learning curve and the angulation of the baseplate to the sclera is critical. Repeated SCITA injections are effective and without apparent clinically evident complications. It may be used as an alternative to intravitreal injection of Ozurdex.

Financial Disclosure

None